[F]Fluoroethyltyrosine–Positron Emission Tomography-Based Therapy Monitoring after Stereotactic Iodine-125 Brachytherapy in Patients with Recurrent High-Grade Glioma
Therapy monitoring of glioma after stereotactic iodine-125 brachytherapy (SBT) remains challenging because posttherapeutic changes in magnetic resonance imaging can mimic tumor progression. We evaluated the prognostic value of serial [ 18 F]fluoroethyltyrosine (FET)-positron emission tomographic (PE...
Saved in:
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2013-05-01
|
| Series: | Molecular Imaging |
| Online Access: | https://doi.org/10.2310/7290.2012.00027 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1841561888521977856 |
|---|---|
| author | Nathalie L. Jansen Bogdana Suchorska Silke B. Schwarz Sabina Eigenbrod Juergen Lutz Vera Graute Peter Bartenstein Claus Belka Friedrich W. Kreth Christian la Fougère |
| author_facet | Nathalie L. Jansen Bogdana Suchorska Silke B. Schwarz Sabina Eigenbrod Juergen Lutz Vera Graute Peter Bartenstein Claus Belka Friedrich W. Kreth Christian la Fougère |
| author_sort | Nathalie L. Jansen |
| collection | DOAJ |
| description | Therapy monitoring of glioma after stereotactic iodine-125 brachytherapy (SBT) remains challenging because posttherapeutic changes in magnetic resonance imaging can mimic tumor progression. We evaluated the prognostic value of serial [ 18 F]fluoroethyltyrosine (FET)-positron emission tomographic (PET) scans for therapy monitoring of high-grade glioma (HGG) after SBT. Thirty-three patients with recurrent HGG were included. Serial FET-PET scans were performed prior to therapeutic intervention and at 3-month intervals during the first year after SBT. FET-PET evaluation was performed by both conventional data analysis and kinetic analysis. Prognostic factors were obtained from proportional hazard models. Median local progression-free survival (LPFS) was 11.1 months. Maximal standardized background uptake value (SUV max /BG) and biologic tumor volume (BTV) differentiated accurately between therapeutic effects and local tumor progression at the 6-month and subsequent examinations. Increasing uptake kinetics at baseline ( p < .05) and during follow-up ( p < .01) were stringently associated with a longer LPFS. Early increase in FET uptake after SBT is not unequivocally associated with tumor progression; it might be induced by reactive changes and could easily lead to a misclassification of the tumor status (pseudoprogression). Six months after SBT (or later), however, increased SUV max /BG and BTV values are associated with a worse prognosis. Multivariate analysis stresses the prognostic importance of dynamic studies. |
| format | Article |
| id | doaj-art-da3ca7694f5d4e7480b0af5adfc5dc63 |
| institution | Kabale University |
| issn | 1536-0121 |
| language | English |
| publishDate | 2013-05-01 |
| publisher | SAGE Publishing |
| record_format | Article |
| series | Molecular Imaging |
| spelling | doaj-art-da3ca7694f5d4e7480b0af5adfc5dc632025-01-03T01:20:02ZengSAGE PublishingMolecular Imaging1536-01212013-05-011210.2310/7290.2012.0002710.2310_7290.2012.00027[F]Fluoroethyltyrosine–Positron Emission Tomography-Based Therapy Monitoring after Stereotactic Iodine-125 Brachytherapy in Patients with Recurrent High-Grade GliomaNathalie L. JansenBogdana SuchorskaSilke B. SchwarzSabina EigenbrodJuergen LutzVera GrautePeter BartensteinClaus BelkaFriedrich W. KrethChristian la FougèreTherapy monitoring of glioma after stereotactic iodine-125 brachytherapy (SBT) remains challenging because posttherapeutic changes in magnetic resonance imaging can mimic tumor progression. We evaluated the prognostic value of serial [ 18 F]fluoroethyltyrosine (FET)-positron emission tomographic (PET) scans for therapy monitoring of high-grade glioma (HGG) after SBT. Thirty-three patients with recurrent HGG were included. Serial FET-PET scans were performed prior to therapeutic intervention and at 3-month intervals during the first year after SBT. FET-PET evaluation was performed by both conventional data analysis and kinetic analysis. Prognostic factors were obtained from proportional hazard models. Median local progression-free survival (LPFS) was 11.1 months. Maximal standardized background uptake value (SUV max /BG) and biologic tumor volume (BTV) differentiated accurately between therapeutic effects and local tumor progression at the 6-month and subsequent examinations. Increasing uptake kinetics at baseline ( p < .05) and during follow-up ( p < .01) were stringently associated with a longer LPFS. Early increase in FET uptake after SBT is not unequivocally associated with tumor progression; it might be induced by reactive changes and could easily lead to a misclassification of the tumor status (pseudoprogression). Six months after SBT (or later), however, increased SUV max /BG and BTV values are associated with a worse prognosis. Multivariate analysis stresses the prognostic importance of dynamic studies.https://doi.org/10.2310/7290.2012.00027 |
| spellingShingle | Nathalie L. Jansen Bogdana Suchorska Silke B. Schwarz Sabina Eigenbrod Juergen Lutz Vera Graute Peter Bartenstein Claus Belka Friedrich W. Kreth Christian la Fougère [F]Fluoroethyltyrosine–Positron Emission Tomography-Based Therapy Monitoring after Stereotactic Iodine-125 Brachytherapy in Patients with Recurrent High-Grade Glioma Molecular Imaging |
| title | [F]Fluoroethyltyrosine–Positron Emission Tomography-Based Therapy Monitoring after Stereotactic Iodine-125 Brachytherapy in Patients with Recurrent High-Grade Glioma |
| title_full | [F]Fluoroethyltyrosine–Positron Emission Tomography-Based Therapy Monitoring after Stereotactic Iodine-125 Brachytherapy in Patients with Recurrent High-Grade Glioma |
| title_fullStr | [F]Fluoroethyltyrosine–Positron Emission Tomography-Based Therapy Monitoring after Stereotactic Iodine-125 Brachytherapy in Patients with Recurrent High-Grade Glioma |
| title_full_unstemmed | [F]Fluoroethyltyrosine–Positron Emission Tomography-Based Therapy Monitoring after Stereotactic Iodine-125 Brachytherapy in Patients with Recurrent High-Grade Glioma |
| title_short | [F]Fluoroethyltyrosine–Positron Emission Tomography-Based Therapy Monitoring after Stereotactic Iodine-125 Brachytherapy in Patients with Recurrent High-Grade Glioma |
| title_sort | f fluoroethyltyrosine positron emission tomography based therapy monitoring after stereotactic iodine 125 brachytherapy in patients with recurrent high grade glioma |
| url | https://doi.org/10.2310/7290.2012.00027 |
| work_keys_str_mv | AT nathalieljansen ffluoroethyltyrosinepositronemissiontomographybasedtherapymonitoringafterstereotacticiodine125brachytherapyinpatientswithrecurrenthighgradeglioma AT bogdanasuchorska ffluoroethyltyrosinepositronemissiontomographybasedtherapymonitoringafterstereotacticiodine125brachytherapyinpatientswithrecurrenthighgradeglioma AT silkebschwarz ffluoroethyltyrosinepositronemissiontomographybasedtherapymonitoringafterstereotacticiodine125brachytherapyinpatientswithrecurrenthighgradeglioma AT sabinaeigenbrod ffluoroethyltyrosinepositronemissiontomographybasedtherapymonitoringafterstereotacticiodine125brachytherapyinpatientswithrecurrenthighgradeglioma AT juergenlutz ffluoroethyltyrosinepositronemissiontomographybasedtherapymonitoringafterstereotacticiodine125brachytherapyinpatientswithrecurrenthighgradeglioma AT veragraute ffluoroethyltyrosinepositronemissiontomographybasedtherapymonitoringafterstereotacticiodine125brachytherapyinpatientswithrecurrenthighgradeglioma AT peterbartenstein ffluoroethyltyrosinepositronemissiontomographybasedtherapymonitoringafterstereotacticiodine125brachytherapyinpatientswithrecurrenthighgradeglioma AT clausbelka ffluoroethyltyrosinepositronemissiontomographybasedtherapymonitoringafterstereotacticiodine125brachytherapyinpatientswithrecurrenthighgradeglioma AT friedrichwkreth ffluoroethyltyrosinepositronemissiontomographybasedtherapymonitoringafterstereotacticiodine125brachytherapyinpatientswithrecurrenthighgradeglioma AT christianlafougere ffluoroethyltyrosinepositronemissiontomographybasedtherapymonitoringafterstereotacticiodine125brachytherapyinpatientswithrecurrenthighgradeglioma |